Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RSVPreF3 Maternal Vaccine Phase 2 Study
NCT04126213Phase 2Completed
- Sponsor
- GSK
- Start
- Nov 2019
- Primary completion
- Jul 2020
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 9
01
Overview
Phase 2, randomised, double-blind trial of respiratory syncytial virus vaccine, recombinant, adjuvanted in respiratory syncytial virus infection (RSV) (3 arms), sponsored by GSK. Primary endpoints: Percentage of Maternal Subjects With Any Solicited Administration Site Events at 7 days, Percentage of Maternal Subjects With Any Solicited Systemic Events at 7 days and 6 more. Started Nov 2019; status: completed.
02
Drugs
respiratory syncytial virus vaccine, recombinant, adjuvanted
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT04126213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04126213.